📰 Nuclear Export News
Page 13 - Nuclear Export News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nuclear Export. Real-time updates on events, politics, business and more.
August 4, 2022
– Achieved Second Quarter 2022 Total Revenue of $39.7 Million, Up 76% Versus Second Quarter 2021; XPOVIO® (selinexor) Net Product Revenue of $29.0 Million, a...
August 1, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
August 1, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
July 28, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...
July 21, 2022
- Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication - - Approval Follows Positive Opinion by European Committee for Medicinal Products for Human Use (CHMP) in May 2022 - NEWTON, Mass.andFLORENCE, Italy, July 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharm...
July 20, 2022
Dupont Capital Management Corp lowered its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) by 56.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,727 shares of the company’s stock after selling 29,675 shares during the period. Dupont Capital Management Corp’s holdings […]
July 20, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced new...
July 1, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
June 15, 2022
Item 1.02 Termination of a Material Definitive Agreement. On June 7, 2022, Karyopharm Therapeutics Inc. received written notice from Biogen MA Inc. that Biogen has elected to terminate the Asset... | June 15, 2022
June 10, 2022
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) Director Deepika Pakianathan sold 325,977 shares of the business’s stock in a transaction that occurred on Wednesday, June 8th. The stock was sold at an average price of $6.50, for a total transaction of $2,118,850.50. Following the transaction, the director now owns 18,731 shares of the company’s stock, […]